Drug Topics

DECEMBER 26, 2024

Check out this list of our top 5 most read cardiology stories from the year 2024.

98

98

Pharmacy Times

DECEMBER 26, 2024

Here is an updated overview of the role of BCMA-directed therapies following the 2024 ASCO Annual Meeting and EHA Congress.

94

94

The Checkup by Singlecare

DECEMBER 26, 2024

2024 has been a busy year for new drugs. Over 40 new medications have been approved by the FDA, giving patients more options for treating various health problems. These new drugs cover a wide range of conditions, from urinary tract infections to rare genetic disorders. Notable new drugs approved in 2024 By staying up-to-date on the latest drug approvals, pharmacists can give new advice when working with patients and other healthcare providers.

FDA 52

FDA Dosage Immunization Hospitals 52

Pharmacy Times

DECEMBER 26, 2024

High levels of the Oscillibacter genus of bacteria were associated with reduced cholesterol.

65

65

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Pharmaceutical Technology

DECEMBER 26, 2024

A $4.75m grant will support the development of EIS-12656, which is being studied alone and in combination with PARP inhibitors.

52

52

Pharmacy Times

DECEMBER 26, 2024

Yi Lin, MD, PhD, highlights the importance of achieving MRD negativity in multiple myeloma, CAR T-cell therapy outcomes, and the critical role of pharmacists in patient care.

Patient Care 65

Patient Care 65

PharmExec

DECEMBER 26, 2024

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

52

52

Compounding Pharmacy of America

DECEMBER 26, 2024

Learn how dental compounding services provide personalized medication for oral health. Explore solutions for pain relief, dry sockets, and other dental needs. The post A Guide to Dental Compounding Services appeared first on Compounding Pharmacy of America.

Compounding 52

Compounding Compounding Pharmacies 52

Pharmaceutical Commerce

DECEMBER 26, 2024

The top five episodes of our podcast in the year 2024, highlighted.

52

52

PharmExec

DECEMBER 26, 2024

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

52

52

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharmaceutical Technology

DECEMBER 26, 2024

AstraZeneca and Daiichi Sankyo have withdrawn marketing authorisation application in the EU voluntarily, intended for datopotamab deruxtecan.

52

52

PharmExec

DECEMBER 26, 2024

In this part of his Pharmaceutical Executive video interview, Dr. Lawrence B. Werlin, MD, FACOG of HRC Fertility (@md.lawrence.werlin on TikTok), discusses the biggest misconceptions about fertility that he sees circulating on social media and work he does to correct and prevent them.

52

52

Therapeutics Education Collaboration

DECEMBER 26, 2024

In episode 594, Mike and James invite Samantha Moe back to talk about the use of the RSV vaccine in pregnancy. The only way to have an informed conversation around this vaccine is to know the numbers. If you listen to the whole podcast, youll get all the numbers available to date. Show notes Tools for Practice 1)Bumpin Up the Protection? RSV Vaccine in Pregnancy 2) Preventing RSV Infections in Infants 3) Preventing RSV in the elderly In episode 594, Mike and James invite Samantha Moe back to tal

Vaccines 40

Vaccines 40

Pharmaceutical Technology

DECEMBER 26, 2024

Immune globulin (human) is under clinical development by Grifols and currently in Phase II for Tachycardia (Tachyarrhythmias).

Immunization 40

Immunization 40

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

STAT

DECEMBER 26, 2024

Genetic sequences of H5N1 bird flu viruses collected from a person in Louisiana who became severely ill show signs of development of several mutations thought to affect the virus’ ability to attach to cells in the upper airways of humans, the Centers for Disease Control and Prevention reported on Thursday. One of the mutations was also seen in a virus sample taken from a teenager in British Columbia who was in critical condition in a Vancouver hospital for weeks after contracting H5N1.

Hospitals 145

Hospitals 145

Pharmaceutical Technology

DECEMBER 26, 2024

Allergen for Grass Pollen Allergy is under clinical development by Roxall Medizin and currently in Phase II for Grass Pollen Allergy.

40

40

STAT

DECEMBER 26, 2024

The global medical community encountered a highly contagious aerosolized pathogen with no known treatment when the SARS-CoV 2-virus triggered the Covid-19 global pandemic nearly five years ago. Fortunately, Covid responded to treatment with convalescent plasma while other therapies and vaccinations were under development.  Today, the H5N1 avian flu virus, currently lurking in birds and cows, is perhaps only a few mutations away from a potentially similar widespread and deadly outbreak in hu

Vaccines 126

Vaccines FDA 126

Pharmaceutical Technology

DECEMBER 26, 2024

Darigabat is under clinical development by Cerevel Therapeutics and currently in Phase II for Seizures.

40

40

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Fierce Pharma

DECEMBER 26, 2024

As the life sciences industry prepares for a new administration, cutting edge technology and more, there are plenty of challenges in store for 2025and much to be optimistic about, too. Thats according to the Deloitte U.S. Center for Health Solutions, which found in a recent survey of 150 C-suite executives across the global life sciences sphere that 75% of respondents are optimistic about the year ahead.

96

96

Pharmaceutical Technology

DECEMBER 26, 2024

Nelivaptan is under clinical development by HMNC and currently in Phase II for Major Depressive Disorder.

40

40

STAT

DECEMBER 26, 2024

In 2024, STAT’s reporters brought you tons of great journalism, and elsewhere [link to in-case-you-missed it] we’ve given you a compendium of the stories you may have missed on our site. We’ve also collected for you below our annual list of stories that STAT staffers loved, and wish that they had written. (Also check out the  jealousy list  at Bloomberg Businessweek, which had the idea first.

Insurance 106

Insurance 106

Pharmaceutical Technology

DECEMBER 26, 2024

Gene Therapy to Target GD2 for Oncology is under clinical development by Bristol-Myers Squibb and currently in Phase I for Sarcomas.

40

40

STAT

DECEMBER 26, 2024

Here we are, on the cusp of the midway point in a decade that has been, in global health and infectious diseases terms, a lot. The 2020s started with the most severe pandemic since the 1918 Spanish flu. Just as the worst of Covid-19 was starting to ease, the world was introduced to mpox, a cousin of smallpox that went from occasionally infecting people who had contact with infected rodents in forested parts of West and Central Africa to spreading from person to person in Europe, the Americas, an

132

132

Pharmaceutical Technology

DECEMBER 26, 2024

Gene Therapy to Target GD2 for Oncology is under clinical development by Bristol-Myers Squibb and currently in Phase I for Osteosarcoma.

40

40

STAT

DECEMBER 26, 2024

If the last few months are any guide, there will be no shortage of surprises and challenges for the biotech industry in the new year. Donald Trump will begin his second term, possibly bringing along controversial figures to lead health agencies. And biotech startups, which have already endured a prolonged economic downturn, are set to face further financial strain as the Federal Reserve projects higher inflation and fewer interest rate cuts next year.

FDA 78

FDA 78

Pharmaceutical Technology

DECEMBER 26, 2024

Tricaprilin is under clinical development by Cerecin and currently in Phase II for Infantile Spasm (West Syndrome).

40

40

Pharmaceutical Technology

DECEMBER 26, 2024

KGYY-15 is under clinical development by Op-T-Mune and currently in Phase I for Type 1 Diabetes (Juvenile Diabetes).

40

40

Pharmaceutical Technology

DECEMBER 26, 2024

Lidocaine is under clinical development by MEDRx and currently in Pre-Registration for Postherpetic Neuralgia.

40

40

Pharmaceutical Technology

DECEMBER 26, 2024

StemVacs-V is under clinical development by Res Nova Bio and currently in Phase II for Metastatic Breast Cancer.

40

40